Researchers show that the p95HER2-T cell bispecific antibody (TCB) can successfully guide immune cells, known as lymphocytes, directly to cancerous ones for their targeted killing. This direct ...

DURING the course of an investigation 1 into the function and life-cycle of lymphocytes, a number of physical techniques were employed to determine the identity of cells isolated from various sources, ...

Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting ...

Clinical activity with anti–CTLA-4 monoclonal antibodies (mAbs) has paved the way for additional T-cell immunomodulatory monoclonal antibody (mAb) approaches for the treatment of cancer to be ...

Developed by Genentech/IDEC, Rituxan® (rituximab) is a genetically engineered molecule derived from a mouse antibody designed to kill B lymphocytes. B lymphocytes, or B cells, are the white blood ...

Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the ...

Bispecific antibodies are artificial proteins that have promising applications in the field of cancer immunotherapy. They are comprised of two monoclonal antibodies held together by a flexible peptide ...

In a recent study published in Science Immunology, researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations. Study: ...